The so-called 'placebo effect' in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoring

Urology

Volumn 51, Issue 2, 1998, Pages 242-250

  Sech, Scott M ^a,b   Montoya, Juan D ^a,b   Bernier, Pablo A ^a,b   Barnboym, Emma ^a,b   Brown, Sherril ^a,b   Gregory, Allison ^a,b   Roehrborn, Claus G ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Veterans Affairs North Texas Health Care System   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICAL ANALYSIS; URINE FLOW RATE;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLACEBO EFFECT; PROSTATIC HYPERPLASIA; QUESTIONNAIRES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 0032005456     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00609-2     Document Type: Article

References (31)

1. McConnell JD, Barry MJ, Bruskewitz RC, Bueschen AJ, Denton SE, Holtgrewe HL, Lange JL, McClennan BL, Mebust WK, Reilly NJ, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, Number 8. 1994;Maryland Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, Rockville.
2. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATL. The American Urological Association's symptom index for benign prostatic hyperplasia. J Urol. 148:1992;1549-1557.
3. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 33:1995;AS145-AS155.
4. Cockett ATK, Aso Y, Denis L. Murphy G, Khoury S, Abrams P, Barry M, Carlton GE, Fitzpatrick J, Gibbons R, et al: Recommendations of the International Consensus Committee, in Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, and Murphy G, (Eds): The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands, Scientific Communication International, pp 553-564.
5. Shapiro AK, Morris LA. The placebo effect in medical and psychological therapies. Garfield SL, Bergin AE. Handbook of Psychotherapy and Behavior Change. 1978;371 Wiley, New York.
6. Brody H. Placebo effect: an examination of Grunbaum's definition. White L, Tusky B, Schwartz GE. Placebo: Theory, Research, and Mechanisms. 1985;37-58 The Guilford Press, New York.
7. White L, Tursky B, Schwartz GE. Placebo in perspective. White L., Tursky B, Schwartz GE. Placebo: Theory, Research, and Mechanisms. 1985;3-6 The Guilford Press, New York.
8. White L., Tursky B, Schwartz GE. Proposed synthesis of placebo models. White L., Tursky B, Schwartz GE. Placebo: Theory, Research, and Mechanisms. 1985;431-448 The Guilford Press, New York.
9. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. J Am Med Assoc. 271:1994;1609-1614.
10. Roehrborn CG. The placebo effect in the treatment of benign prostatic hyperplasia. Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Textbook of Benign Prostatic Hyperplasia. 1996;Isis Medical Media, Oxford.
11. Lepor H, Knapp-Maloney G, Wozniak-Petrofsky J. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia. Int J Clin Pharmacol. 27:1989;392-397.
12. Lepor H, Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol. 70:1992;2-9. (suppl 1).
13. Lepor H, Meretyk S, Knapp-Maloney G. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J Urol. 147:1992;1554-1557.
14. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 148:1992;1467-1474.
15. Christensen MM, Bendix Holme J, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP, Olesen S, Noer I, Wolf H, Husted SE. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol. 27:1993;39-44.
16. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy: the BPH-ALF group. Lancet. 337:1991;1457-1461.
17. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ, Abrams P. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol. 74:1994;50-56.
18. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ. A randomized placebo controlled clinical trial of the safety and efficacy of therapies in men with clinical benign prostatic hyperplasia. N Eng J Med. 335:1996;533-539.
19. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd K, Milam D, Padley R. Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia in the HYCAT study. Urology. 47:1996;159-168.
20. De la Rosette JJ, D'Ancona FCH, Debruyne FMJ. Current status of thermotherapy of the prostate. J Urol. 157:1997;430-438.
21. Blute ML, Patterson DE, Segura JW, Hellerstein DK, Tomera KM. Transurethral microwave thermotherapy versus sham: a prospective double-blind randomized study (abstract). J Urol. 151:1994;415A.
22. Ogden CW, Reddy P, Johnson H, Ramsay JW, Carter SS. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet. 341:1993;14-17.
23. de la Rosette JJ, de Wildt MJ, Alivizatos G, Froeling FM, Debruyne FM. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology. 44:1994;58-63.
24. de Wildt MJAM, Hubregtse M, Ogden C, Carter SSC, Debruyne FMJ, de la Rosette JJMCH. A 12-month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol. 77:1996;221-227.
25. Bdesha AS, Bunce CJ, Snell ME, Witherow RO'N. A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J Urol. 152:1994;453-458.
26. Mayer R, Blute M, Bruskewitz R, Larson T, Utz W. U.S. multi-center study results of a new high temperature microwave system for BPH show improvement in patients symptoms and flow rates without compromise in morbidity and anaesthetic needs (abstract). J Urol. 157:1997;95A.
27. Reynard J, Lim C-S, Abrams P. The value of multiple free-flow studies in men with lower urinary tract symptoms (LUTS) (abstract). J Urol. 153:1995;397A.
28. Roehrborn CG, Preminger G, Newhall P, Denstedt J, Razvi H, Chin LJ, Perlmutter A, Barzell W, Whitmore W, Fritzsch R, et al. Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. Urology. 51:1997;19-28.
29. Oesterling JE, Issa MM, Roehrborn CG, Bruskewitz R, Naslung MJ, Perez-Marrero R, Shumaker BP. Long-term results of a prospective randomized clinical trial comparing TUNA to TURP for the treatment of symptomatic BPH (abstract). J Urol. 157:1997;328A.
30. Pearson K, Lee A. On the law of inheritance in man. Biometrika. 2:1903;357-462.
31. Prescott RJ, Garraway WM. Regression to the mean occurs in measuring peak urinary flow. Br J Urol. 76:1995;611-613.